Evidence-based recommendations for the practical management of Familial Mediterranean Fever

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 3, 2013, Pages 387-391

  Hentgen, Véronique ^a   Grateau, Gilles ^b   Kone Paut, Isabelle ^c   Livneh, Avi ^d   Padeh, Shai ^e   Rozenbaum, Michael ^f   Amselem, Serge ^g   Gershoni Baruch, Ruth ^f   Touitou, Isabelle ^h   Ben Chetrit, Eldad ⁱ  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b HÔPITAL TENON   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d SHEBA MEDICAL CENTER   (Israel)

^e HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g Assistance publique Hôpitaux de Paris   (France)

^h INSERM   (France)

ⁱ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Biological agents; Colchicine; Colchicine resistance; Consensus development conference; Familial Mediterranean fever; Genetic analysis; Guidelines; Review; Siblings; Therapy

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SERUM AMYLOID A; TUMOR NECROSIS FACTOR INHIBITOR;

AMYLOIDOSIS; ARTICLE; ASYMPTOMATIC DISEASE; DRUG DOSE INCREASE; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC SCREENING; HUMAN; MAXIMUM TOLERATED DOSE; MEFV GENE; NEPHROTIC SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEINURIA; SIBLING;

BIOLOGICAL AGENTS; COLCHICINE; COLCHICINE RESISTANCE; CONSENSUS DEVELOPMENT CONFERENCE; FAMILIAL MEDITERRANEAN FEVER; GENETIC ANALYSIS; GUIDELINES; REVIEW; SIBLINGS; THERAPY;

ADULT; CHILD; COLCHICINE; CONSENSUS; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FAMILIAL MEDITERRANEAN FEVER; HUMANS;

EID: 84889574819     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.04.011     Document Type: Article

References (62)

1. Ben-Chetrit E., Levy M. Familial Mediterranean fever. Lancet 1998, 351(9103):659-664.
2. Grateau G. Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxford) 2004, 43(4):410-415.
3. Goldfinger S.E. Colchicine for familial Mediterranean fever. N Engl J Med 1972, 287(25):1302.
4. Kosan C., Ozkan B. Once-daily use of colchicine in children with familial Mediterranean fever. Clin Pediatr (Phila) 2004, 43(7):605-608.
5. Ozkan E., Okur O., Ekmekci A., Ozcan R., Tag T. A new approach to the treatment of periodic fever. Med Bull Istanbul Med Fac 1972, 5:44-49.
6. Dougados M. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004, 63(9):1172-1176.
7. Ruperto N., Meiorin S., Iusan S.M., Ravelli A., Pistorio A., Martini A. Consensus procedures and their role in pediatric rheumatology. Curr Rheumatol Rep 2008, 10(2):142-146.
8. Zemer D., Revach M., Pras M., Modan B., Schor S., Sohar E., et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med 1974, 291(18):932-934.
9. Dinarello C.A., Wolff S.M., Goldfinger S.E., Dale D.C., Alling D.W. Colchicine therapy for familial Mediterranean fever. A double-blind trial. N Engl J Med 1974, 291(18):934-937.
10. Goldstein R.C., Schwabe A.D. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study. Ann Intern Med 1974, 81(6):792-794.
11. Zemer D., Pras M., Sohar E., Modan M., Cabili S., Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986, 314(16):1001-1005.
12. Cabili S., Zemer D., Pras M., Aviram A., Sohar E., Gafni J. The prevention of amyloidosis in familial Mediterranean fever with colchicine. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985, 21:709-711.
13. Keizman I.K., Greenwald M., Ravid M. Colchicine inhibition of the first phase of amyloid synthesis in experimental animals. Br J Exp Pathol 1976, 57(6):686-688.
14. Livneh A., Zemer D., Langevitz P., Laor A., Sohar E., Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994, 37(12):1804-1811.
15. Livneh A., Zemer D., Siegal B., Laor A., Sohar E., Pras M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 1992, 60(4):418-422.
16. Simşek B., Işlek I., Simşek T., Küçüködük S., Cengiz K. Regression of nephrotic syndrome due to amyloidosis secondary to familial Mediterranean fever following colchicine treatment. Nephrol Dial Transplant 2000, 15(2):281-282.
17. Kallinich T., Haffner D., Niehues T., Huss K., Lainka E., Neudorf U., et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007, 119(2):e474-e483.
18. Ozturk M.A., Kanbay M., Kasapoglu B., Onat A.M., Guz G., Furst D.E., et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 2011, 29(4 Suppl. 67):S77-S86.
19. Terkeltaub R.A., Furst D.E., Digiacinto J.L., Kook K.A., Davis M.W. Evidence basis of a novel colchicine dose reduction algorithm to predict & prevent colchicine toxicity in the presence of P-gp/CYP P450 3A4 inhibitors. Arthritis Rheum 2011, 63(8):2226-2237.
20. Terkeltaub R.A. Colchicine update: 2008. Semin Arthritis Rheum 2009, 38(6):411-419.
21. Ben-Chetrit E., Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998, 28(1):48-59.
22. Lidar M., Scherrmann J.-M., Shinar Y., Chetrit A., Niel E., Gershoni-Baruch R., et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004, 33(4):273-282.
23. Padeh S., Gerstein M., Berkun Y. Colchicine is a safe drug in children with familial Mediterranean fever. J Pediatr 2012, 161(6):1142-1146.
24. Majeed H.A., Barakat M. Familial Mediterranean fever (recurrent hereditary polyserositis) in children: analysis of 88 cases. Eur J Pediatr 1989, 148(7):636-641.
25. Zemer D., Livneh A., Danon Y.L., Pras M., Sohar E. Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum 1991, 34(8):973-977.
26. Ben-Chetrit E., Aamar S. About colchicine compliance, resistance and virulence. Clin Exp Rheumatol 2009, 27(2 Suppl. 53):S1-S3.
27. Korkmaz C. Therapeutic approach to patients with familial Mediterranean fever-related amyloidosis resistant to colchicine. Clin Exp Rheumatol. 30 2012, (3 Suppl. 72):S104-S107.
28. Ozen S., Bilginer Y., Ayaz N.A., Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011, 38(3):516-518.
29. Vandecasteele S.J., Paepe P.D., Vriese A.S.D. Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated alpha-2a interferon. Clin Nephrol 2011, 75(Suppl. 1):1-3.
30. Rozenbaum M., Boulman N., Feld J., Avshovich N., Petrovich S., Elias M., et al. Intravenous colchicine treatment for six months: adjunctive therapy in familial Mediterranean fever (FMF) unresponsive to oral colchicine. Clin Exp Rheumatol 2009, 27(2 Suppl. 53):S105.
31. Bezalel Y., Gershoni-Baruch R., Dagan E., Lidar M., Livneh A. The 3435 T polymorphism in the ABCB1 gene and colchicine unresponsiveness in familial Mediterranean fever. Clin Exp Rheumatol. 27 2009, (2 Suppl. 53):S103-S104.
32. Seyahi E., Ozdogan H., Celik S., Ugurlu S., Yazici H. Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006, 24(5 Suppl. 42):S99-103.
33. Calguneri M., Apras S., Ozbalkan Z., Ozturk M.A., Ertenli I., Kiraz S. The efficacy of continuous interferon alpha administration as an adjunctive agent to colchicine-resistant familial Mediterranean fever patients. Clin Exp Rheumatol 2004, 22(4 Suppl. 34):S41-S44.
34. Tunca M., Akar S., Soytürk M., Kirkali G., Resmi H., Akhunlar H., et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: a double-blind, placebo-controlled trial. Clin Exp Rheumatol. 22 2004, (4 Suppl. 34):S37-S40.
35. Ben-Chetrit E., Ozdogan H. Non-response to colchicine in FMF-definition, causes and suggested solutions. Clin Exp Rheumatol 2008, 26(4 Suppl. 50):S49-S51.
36. Tunca M., Tankurt E., Akpinar H.A., Akar S., Hizli N., Gönen O. The efficacy of interferon alpha on colchicine-resistant familial Mediterranean fever attacks: a pilot study. Br J Rheumatol 1997, 36(9):1005-1008.
37. Bilgen S.A., Kilic L., Akdogan A., Kiraz S., Kalyoncu U., Karadag O., et al. Effects of anti-tumor necrosis factor agents for familial Mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment. J Clin Rheumatol 2011, 17(7):358-362.
38. Amaryan G., Astvatsatryan V., Gabrielyan E., Panossian A., Panosyan V., Wikman G. Double-blind, placebo-controlled, randomized, pilot clinical trial of ImmunoGuard-a standardized fixed combination of Andrographis paniculata Nees, with Eleutherococcus senticosus Maxim, Schizandra chinensis Bail. and Glycyrrhiza glabra L. extracts in patients with Familial Mediterranean Fever. Phytomedicine 2003, 10(4):271-285.
39. Chae J.J., Wood G., Masters S.L., Richard K., Park G., Smith B.J., et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A 2006, 103(26):9982-9987.
40. Papin S., Cuenin S., Agostini L., Martinon F., Werner S., Beer H.-D., et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ 2007, 14(8):1457-1466.
41. Meinzer U., Quartier P., Alexandra J.-F., Hentgen V., Retornaz F., Koné-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011, 41(2):265-271.
42. Gattringer R., Lagler H., Gattringer K.B., Knapp S., Burgmann H., Winkler S., et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 2007, 37(11):912-914.
43. Kuijk L.M., Govers A.M.A.P., Frenkel J., Hofhuis W.J.D. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007, 66(11):1545-1546.
44. Belkhir R., Moulonguet-Doleris L., Hachulla E., Prinseau J., Baglin A., Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007, 146(11):825-826.
45. Moser C., Pohl G., Haslinger I., Knapp S., Rowczenio D., Russel T., et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009, 24(2):676-678.
46. Mitroulis I., Papadopoulos V.P., Konstantinidis T., Ritis K. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient. Neth J Med 2008, 66(11):489-491.
47. Mitroulis I., Skendros P., Oikonomou A., Tzioufas A.G., Ritis K. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis. Ann Rheum Dis 2011, 70(7):1347-1348.
48. Bilginer Y., Ayaz N.A., Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol 2010, 29(2):209-210.
49. Alpay N., Sumnu A., Calişkan Y, Yazici H, Türkmen A., Gül A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int 2012, ;32(10):3277-9 [Internet] Available from: 〈http://dx.doi.org/10.1007/s00296-010-1474-6〉.
50. Hashkes P.J., Spalding S.J., Giannini E.H., Huang B., Johnson A., Park G., et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean Fever: a randomized trial. Ann Intern Med 2012, 157(8):533-541.
51. Sakallioglu O., Duzova A., Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol 2006, 24(4):435-437.
52. Ozgocmen S., Akgul O. Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Mod Rheumatol 2011, ;21(6):684-90 [Internet] Available from: 〈http://dx.doi.org/10.1007/s10165-011-0463-2〉.
53. Akgul O., Kilic E., Kilic G., Ozgocmen S. Efficacy and safety of biologic treatments in familial Mediterranean fever. Am J Med Sci 2012, ePub ahead of print.
54. Ben-Chetrit E., Sagi M. Genetic counselling in familial Mediterranean fever: has the time come?. Rheumatology (Oxford) 2001, 40(6):606-609.
55. Blum A., Gafni J., Sohar E., Shibolet S., Heller H. Amyloidosis as the sole manifestation of familial Mediterranean fever (FMF). Further evidence of its genetic nature. Ann Intern Med 1962, 57:795-799.
56. Korkmaz C., Ozdogan H., Kasapçopur O., Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis 2002, 61(1):79-81.
57. Duzova A., Bakkaloglu A., Besbas N., Topaloglu R., Ozen S., Ozaltin F., et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 2003, 21(4):509-514.
58. Balci B., Tinaztepe K., Yilmaz E., Guçer S., Ozen S., Topaloǧlu R., et al. MEFV gene mutations in familial Mediterranean fever phenotype II patients with renal amyloidosis in childhood: a retrospective clinicopathological and molecular study. Nephrol Dial Transplant 2002, 17(11):1921-1923.
59. Sohar E., Gafni J., Pras M., Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967, 43(2):227-253.
60. Saatçi U., Ozen S., Ozdemir S., Bakkaloglu A., Besbas N., Topaloglu R., et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 1997, 156(8):619-623.
61. Melikoǧlu M., Ozdoǧan H., Korkmaz C., Kasapçopur O., Arisoy N., Akkuş S., et al. A survey of phenotype II in familial Mediterranean fever. Ann Rheum Dis 2000, 59(11):910-913.
62. Camus D., Shinar Y., Aamar S., Langevitz P., Ben-Zvi I., Livneh A., et al. 'Silent' carriage of two familial Mediterranean fever gene mutations in large families with only a single identified patient. Clin Genet 2012, 82(3):288-291.